Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Equity Average (2016 - 2025)

Rocket Pharmaceuticals' Equity Average history spans 10 years, with the latest figure at $295.4 million for Q4 2025.

  • For Q4 2025, Equity Average fell 25.49% year-over-year to $295.4 million; the TTM value through Dec 2025 reached $295.4 million, down 25.49%, while the annual FY2025 figure was $370.2 million, 22.53% down from the prior year.
  • Equity Average for Q4 2025 was $295.4 million at Rocket Pharmaceuticals, down from $333.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $516.8 million in Q4 2023 and bottomed at $295.4 million in Q4 2025.
  • The 5-year median for Equity Average is $433.5 million (2022), against an average of $427.9 million.
  • The largest annual shift saw Equity Average soared 91.81% in 2021 before it fell 25.49% in 2025.
  • A 5-year view of Equity Average shows it stood at $470.2 million in 2021, then fell by 8.87% to $428.5 million in 2022, then increased by 20.61% to $516.8 million in 2023, then dropped by 23.28% to $396.5 million in 2024, then dropped by 25.49% to $295.4 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Equity Average are $295.4 million (Q4 2025), $333.9 million (Q3 2025), and $383.2 million (Q2 2025).